Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VYGR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The Chief Financial Officer resigned to pursue a new opportunity, triggering a leadership transition in the finance function.
Voyager Therapeutics CFO Nathan Jorgensen resigns; COO Robin Swartz to assume finance role
Filed April 21, 2026 · Period ending April 15, 2026 · ~1 min read
Key Changes
-
high
CFO Nathan Jorgensen resigned effective May 8, 2026, to pursue a new opportunity. The company stated his departure was not due to any disagreement with management or the board.
Item 5.02 verify on EDGAR → -
high
Robin Swartz, current COO and Chief Business Officer, will assume principal financial officer and treasurer roles. Swartz previously served as interim principal financial officer in 2024 and has over 10 years of finance experience at Sanofi Genzyme.
Item 5.02 verify on EDGAR → -
medium
Amy Quinlan, VP of Finance since January 2025, appointed principal accounting officer. She brings controller and finance leadership experience from Vor Biopharma and Tetraphase Pharmaceuticals.
Item 5.02 verify on EDGAR →
Summary
Voyager Therapeutics announced the resignation of CFO Nathan Jorgensen, effective May 8, 2026. While the company emphasized his departure was voluntary and not due to any disagreement, CFO transitions always warrant attention as they can signal strategic shifts or operational challenges.
The company is filling the gap internally, appointing COO Robin Swartz as principal financial officer and VP of Finance Amy Quinlan as principal accounting officer. For retail investors, the key positive is continuity: Swartz previously served as interim principal financial officer in 2024 and has extensive finance experience from Sanofi Genzyme, suggesting she can step into the role smoothly.
Quinlan's controller background provides accounting depth. The internal promotions avoid the uncertainty of an external search. Watch for the next quarterly earnings call and 10-Q filing to assess whether the finance transition affects reporting quality or strategic execution. Any delays in SEC filings or changes in financial guidance could indicate integration challenges with the new leadership structure.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
CFO Nathan Jorgensen resigned effective May 8, 2026; Robin Swartz appointed principal financial officer and Amy Quinlan appointed principal accounting officer.
Added in current filing · verify on EDGAR →
On April 15, 2026, Nathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective May 8, 2026 (the effective time of Dr. Jorgensen’s transition, the “Effective Time”), to pursue a new opportunity. Dr. Jorgensen’s resignation is not a result of any disagreement with the Company.
The Chief Financial Officer, Nathan Jorgensen, resigned effective May 8, 2026, to pursue a new opportunity. The company explicitly stated his resignation was not due to any disagreement with the company. This represents a key leadership change in the finance function.
Added in current filing · verify on EDGAR →
In connection with the transition of Dr. Jorgensen, on April 20, 2026, the board of directors of the Company appointed Robin Swartz to assume the roles of principal financial officer and treasurer of the Company, effective as of the Effective Time.
Robin Swartz, currently Chief Operating Officer and Chief Business Officer, was appointed to assume the principal financial officer and treasurer roles effective May 8, 2026. Swartz has prior experience as the company's principal financial officer from April 2024 to July 2024 and spent over ten years in finance roles at Sanofi Genzyme, providing continuity during the CFO transition.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify